Sugi Predict

Sugi Predict / Targets / GMDS

GMDS

GDP-mannose 4,6 dehydratase · O60547 · GMDS on Sugi Atlas →

1,893 patent compounds predicted against GMDS, 1,676 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Molibresib Molibresib (SCHEMBL1872390) 1.00 1/20
Molibresib Molibresib (SCHEMBL12671490) 1.00 1/20
Molibresib Molibresib (SCHEMBL12966358) 1.00 1/20
SCHEMBL9998851 SCHEMBL9998851 0.91 1/20
SCHEMBL14756282 SCHEMBL14756282 0.88 1/20
SCHEMBL15980874 SCHEMBL15980874 0.88 1/20
SCHEMBL12966165 SCHEMBL12966165 0.87 1/20
SCHEMBL14756215 SCHEMBL14756215 0.87 1/20
SCHEMBL14756339 SCHEMBL14756339 0.87 1/20
SCHEMBL15980861 SCHEMBL15980861 0.87 1/20
SCHEMBL9998825 SCHEMBL9998825 0.86 1/20
SCHEMBL15980893 SCHEMBL15980893 0.86 1/20
SCHEMBL15980803 SCHEMBL15980803 0.86 1/20
SCHEMBL1874116 SCHEMBL1874116 0.85 1/20
SCHEMBL12671221 SCHEMBL12671221 0.85 1/20
SCHEMBL14756021 SCHEMBL14756021 0.85 1/20
SCHEMBL14756240 SCHEMBL14756240 0.85 1/20
SCHEMBL14756287 SCHEMBL14756287 0.85 1/20
SCHEMBL14756335 SCHEMBL14756335 0.85 1/20
SCHEMBL14756409 SCHEMBL14756409 0.85 1/20

Clinical trials — most relevant to GMDS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease PHASE3COMPLETED
Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial PHASE3COMPLETED
Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) PHASE1/PHASE2COMPLETED
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses PHASE2COMPLETED
Multi-Center Study of ManNAc for GNE Myopathy PHASE2ACTIVE_NOT_RECRUITING
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy PHASE2UNKNOWN
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis PHASE2ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults PHASE1RECRUITING
Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects PHASE1UNKNOWN
Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects PHASE1UNKNOWN
Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection PHASE1COMPLETED
Registry Gangliosidoses nanUNKNOWN
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease nanNO_LONGER_AVAILABLE
Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder nanUNKNOWN
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC nanRECRUITING
Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C nanUNKNOWN
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB nanCOMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Omics Gaucher Study: Multiomic Approach nanACTIVE_NOT_RECRUITING
Miglustat on Gaucher Disease Type IIIB nanUNKNOWN
Study of Glycogen Storage Disease Expression in Carriers nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GMDS binder may also engage these)

ProteinNameSimilarity
Q8K0C9 — 1.000 Q8K0C9 →
Q8K3X3 — 1.000 Q8K3X3 →
A8Y0L5 — 0.993 A8Y0L5 →
O45583 — 0.993 O45583 →
Q9SNY3 — 0.991 Q9SNY3 →
P0AC90 — 0.991 P0AC90 →
P93031 — 0.990 P93031 →
Q56872 — 0.990 Q56872 →
Q56598 — 0.988 Q56598 →
Q18801 — 0.987 Q18801 →
Q06952 — 0.987 Q06952 →
P0AC91 — 0.986 P0AC91 →
P0AC89 — 0.986 P0AC89 →
Q43070 — 0.986 Q43070 →
P0AC88 — 0.986 P0AC88 →
P55354 — 0.986 P55354 →
Q9JRN5 — 0.986 Q9JRN5 →
Q1ZXF7 — 0.985 Q1ZXF7 →
Q9LH76 — 0.985 Q9LH76 →
Q9VMW9 — 0.984 Q9VMW9 →
Q42605 — 0.984 Q42605 →
P56985 — 0.983 P56985 →
Q9Y7X5 — 0.983 Q9Y7X5 →
P56986 — 0.983 P56986 →
P18645 — 0.982 P18645 →
O65780 — 0.982 O65780 →
Q9SYM5 — 0.982 Q9SYM5 →
Q9LPG6 — 0.982 Q9LPG6 →
Q51366 — 0.981 Q51366 →
Q652A8 — 0.981 Q652A8 →